Bavisant (also known as JNJ-31001074) is a novel, highly selective, orally bioactive antagonist of the human H3 receptor with a novel mechanism of action which involves wakefulness and cognition. It could be applied as an ADHD treatment. H3 antagonists may help with impulsivity and attention since histamine H3 receptors are found on non-histamine neurons and control other neurotransmitters like acetylcholine and norepinephrine. Research suggests that H3 receptor antagonists may have a special therapeutic effect and provide a significant alternative for the treatment of ADHD because of their novel mechanism of action.
Physicochemical Properties
| Molecular Formula | C19H27N3O2 |
| Molecular Weight | 329.43658 |
| Exact Mass | 329.21 |
| Elemental Analysis | C, 69.27; H, 8.26; N, 12.76; O, 9.71 |
| CAS # | 929622-08-2 |
| Related CAS # | Bavisant dihydrochloride hydrate; 1103522-80-0; Bavisant dihydrochloride; 929622-09-3 |
| PubChem CID | 16061509 |
| Appearance | Light yellow to brown solid powder |
| LogP | 1.252 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 24 |
| Complexity | 418 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C(N1CCN(C2CC2)CC1)C(C=C3)=CC=C3CN4CCOCC4 |
| InChi Key | BGBVSGSIXIIREO-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C19H27N3O2/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20/h1-4,18H,5-15H2 |
| Chemical Name | (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone |
| Synonyms | JNJ-31001074; JNJ31001074; JNJ 31001074; Bavisant dihydrochloride |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | H3 receptor |
| ln Vitro | Bavisant raises acetylcholine levels in rat frontal cortex[4]. |
| ln Vivo | Bavisant increases acetylcholine levels in the frontal cortex of rats [4]. |
| References |
[1]. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. J Med Chem. 2011 Jul 14;54(13):4781-92. [2]. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34. [3]. Identification of novel β-lactams and pyrrolidinone derivatives as selective Histamine-3 receptor (H3R) modulators as possible anti-obesity agents. Eur J Med Chem. 2018 May 25;152:148-159. [4]. Histamine H3 receptor antagonists/inverse agonists: Where do they go? Pharmacol Ther. 2019 Aug;200:69-84. |
| Additional Infomation | Bavisant has been used in trials studying the basic science and treatment of Alcoholism, Pharmacokinetics, Drug Interactions, Attention Deficit Hyperactivity Disorder, and Attention Deficit Disorders With Hyperactivity. |
Solubility Data
| Solubility (In Vitro) | DMSO: ~100 mg/mL (~303.6 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0355 mL | 15.1773 mL | 30.3545 mL | |
| 5 mM | 0.6071 mL | 3.0355 mL | 6.0709 mL | |
| 10 mM | 0.3035 mL | 1.5177 mL | 3.0355 mL |